Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
- PMID: 9811915
- DOI: 10.1056/NEJM199811123392001
Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
Abstract
Background: The Pediatric AIDS Clinical Trials Group Protocol 076 reported a reduction in the rate of perinatal transmission of the human immunodeficiency virus (HIV) from 25.5 percent to 8.3 percent with a three-part regimen of zidovudine given ante partum, intra partum, and to the newborn. We examined the effects of abbreviated zidovudine regimens on perinatal HIV transmission using data from the HIV polymerase-chain-reaction (PCR) testing service of the New York State Department of Health. Pregnant women who received abbreviated regimens rather than the recommended regimens did so because of limited prenatal care or by choice.
Methods: The requisition form used by the PCR testing service included information on the demographic characteristics of the infants and the timing of any perinatal treatment with zidovudine. We also analyzed data on the timing of zidovudine prophylaxis collected by chart review in a subgroup of 454 infants as a means of validating the results in the entire cohort.
Results: From August 1, 1995, through January 31, 1997, specimens from 939 HIV-exposed infants who were 180 days of age or younger were submitted for PCR testing. The rates of perinatal HIV transmission varied depending on when zidovudine prophylaxis was begun. When treatment was begun in the prenatal period, the rate of HIV transmission was 6.1 percent (95 percent confidence interval, 4.1 to 8.9 percent); when begun intra partum, the rate was 10.0 percent (3.3 to 21.8 percent); when begun within the first 48 hours of life, the rate was 9.3 percent (4.1 to 17.5 percent); and when begun on day 3 of life or later, the rate was 18.4 percent (7.7 to 34.3 percent). In the absence of zidovudine prophylaxis, the rate of HIV transmission was 26.6 percent (21.1 to 32.7 percent).
Conclusions: These results confirm the efficacy of zidovudine prophylaxis and suggest that there are reductions in the rates of perinatal transmission of HIV even with the use of abbreviated regimens that are begun intra partum or in the first 48 hours of life.
Comment in
-
Short (and shorter) courses of zidovudine.N Engl J Med. 1998 Nov 12;339(20):1467-8. doi: 10.1056/NEJM199811123392009. N Engl J Med. 1998. PMID: 9811923 No abstract available.
-
Short courses of zidovudine and perinatal transmission of HIV.N Engl J Med. 1999 Apr 1;340(13):1040-1; author reply 1042-3. doi: 10.1056/NEJM199904013401312. N Engl J Med. 1999. PMID: 10189281 No abstract available.
-
Short courses of zidovudine and perinatal transmission of HIV.N Engl J Med. 1999 Apr 1;340(13):1041; author reply 1042-3. N Engl J Med. 1999. PMID: 10189282 No abstract available.
-
Short courses of zidovudine and perinatal transmission of HIV.N Engl J Med. 1999 Apr 1;340(13):1041-2; author reply 1042-3. N Engl J Med. 1999. PMID: 10189283 No abstract available.
-
Short courses of zidovudine and perinatal transmission of HIV.N Engl J Med. 1999 Apr 1;340(13):1042-3. N Engl J Med. 1999. PMID: 10189284 No abstract available.
Similar articles
-
A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators.N Engl J Med. 2000 Oct 5;343(14):982-91. doi: 10.1056/NEJM200010053431401. N Engl J Med. 2000. PMID: 11018164 Clinical Trial.
-
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.N Engl J Med. 1994 Nov 3;331(18):1173-80. doi: 10.1056/NEJM199411033311801. N Engl J Med. 1994. PMID: 7935654 Clinical Trial.
-
HIV infection and zidovudine use in childbearing women.Pediatrics. 2004 Dec;114(6):e707-12. doi: 10.1542/peds.2004-0414. Epub 2004 Nov 15. Pediatrics. 2004. PMID: 15545619
-
Preventing perinatal HIV transmission: zidovudine use during pregnancy.Am Fam Physician. 1997 Jan;55(1):171-4, 177-8. Am Fam Physician. 1997. PMID: 9012276 Review.
-
[Reducing perinatal transmission by antiretroviral therapy].Wien Med Wochenschr. 1998;148(23-24):550-5. Wien Med Wochenschr. 1998. PMID: 10189685 Review. German.
Cited by
-
HIV/Tuberculosis Coinfection in Pregnancy and the Postpartum Period.J Clin Med. 2023 Sep 29;12(19):6302. doi: 10.3390/jcm12196302. J Clin Med. 2023. PMID: 37834946 Free PMC article. Review.
-
HIV infection.Nat Rev Dis Primers. 2023 Aug 17;9(1):42. doi: 10.1038/s41572-023-00452-3. Nat Rev Dis Primers. 2023. PMID: 37591865 Review.
-
Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV.Glob Health Sci Pract. 2023 Apr 28;11(2):e2200401. doi: 10.9745/GHSP-D-22-00401. Print 2023 Apr 28. Glob Health Sci Pract. 2023. PMID: 37116934 Free PMC article.
-
Prevention of the Vertical Transmission of HIV; A Recap of the Journey so Far.Viruses. 2023 Mar 26;15(4):849. doi: 10.3390/v15040849. Viruses. 2023. PMID: 37112830 Free PMC article. Review.
-
The End Is in Sight: Current Strategies for the Elimination of HIV Vertical Transmission.Curr HIV/AIDS Rep. 2023 Jun;20(3):121-130. doi: 10.1007/s11904-023-00655-z. Epub 2023 Mar 27. Curr HIV/AIDS Rep. 2023. PMID: 36971951 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical